Introduction Introduction Introduction Introduction
ANCA-associated vasculitis (AAV) constitutes a group of primary vasculitides associated with antineutrophil cytoplasmic antibodies (ANCA). AAV comprise Wegener's Granulomatosis (WG), microscopic polyangiitis (MPA), renal limited vasculitis (RLV) and the Churg-Strauss syndrome (CSS). The etiology of these autoimmune vasculitides is unknown. However, it is tempting to assume that the human leukocyte antigen (HLA) system is involved in the etiology of AAV as the major histocompatibility complex (MHC) plays a central role in the distinction bet-ween self and non-self and is involved in antigen presentation. It is, however, also possible that other immune-modulating genes, like TNF-α and C4A, located near the HLA genes on chromosome 6, are involved in the etiology of autoimmune diseases. The finding of associations between several HLA antigens and several autoimune diseases, for instance DR4 and systemic lupus erythomatosus (SLE), suggests that HLA is indeed involved in the development of these autoimmune diseases.
No definite answers are available concerning the possible relationship between HLA antigens and AAV. In several small studies conflicting data have been presented . Likewise, conflicting data about the relation between HLA antigens and the course of AAV are reported (3;6;10;12;14;16;22) . In other autoimmune diseases certain HLA antigens are associated with the clinical course of the disease. For instance, in patients with SLE, DR3 and DR4 antigens are associated with a lower risk of developing nephritis, in contrast to carriers of DR2 (23) . Identifying patients at risk for relapses or more serious disease before start of treatment will provide tools to tailor the treatment of these AAV patients.
In this study, we investigated the possible association between HLA antigens and AAV in a cohort of 304 patients. Furthermore, we investigated the association between HLA antigens and the severity and course of AAV.
Methods

Methods Methods Methods
Our cohort included all consecutive patients who were diagnosed with AAV in the period 1990-2005, visited our hospital (tertiary referral center for vasculitis), and were classified using the Chapel Hill Consensus Conference definitions for WG, MPA, RLV or CSS (24) . All patients had to have a follow-up of at least two years.
From their records, disease manifestations and disease severity at diagnosis were collected. Disease severity was scored using the Birmingham Vasculitis Activity Score (BVAS) (25) . During follow-up, the patients were checked (both by clinical and laboratory investigations) for disease activity at least every 3 months. ANCA titers were measured every 3 months as well. Relapse was defined as new or increasing disease activity, requiring use of renewed or intensified immune suppressive therapy (26) .
HLA A, B and DR antigens were typed serologically, using a microcytotoxicity assay. In case of an apparent HLA-DR homozygosity, a DNA-based Sequence Specific Priming (SSP) analysis was performed. All HLA-techniques were according to European Federation for Immunogenetics (EFI)-standards. To investigate the 24 possible relationship between HLA antigens and AAV, the prevalence of these HLA antigens in patients with AAV was compared with that of 5872 healthy blood donors, coming from the same region as the majority of our patients. Additionally, we investigated the prevalence of the ancestral haplotype A1B8DR3 in our patients, in comparison with that of 4000 healthy Dutch controls originating from a Eurotransplant database.
In addition to an association with AAV, we investigated the possible relationship between HLA antigens and disease manifestations at diagnosis, ANCA specificity, and the occurrence of relapses within 5 years of diagnosis. Furthermore, the actuarial relapse free survival was calculated per HLA antigen. An analysis of actuarial relapse free survival per HLA antigen per ANCA-specificity was also performed. Finally, the relation between HLA antigens and persistence of ANCA was evaluated by comparing patients who became negative for ANCA and for the subgroups of patients with PR3-ANCA and MPO-ANCA during the first 12 months of follow-up after diagnosis, with those who did not (27) . ANCA titers were measured by indirect immunofluorescence assay, while at diagnosis, PR3-ANCA and MPO-ANCAspecificity was confirmed at least once by an antigen specific capture ELISA assay (28) .
Statistics
Values are presented as medians with ranges unless stated otherwise. Numerical data between groups were compared using the Mann-Whitney U test. To compare proportions of groups both the chi square test and Fisher Exact test were used, when appropriate. Corrections for multiple comparisons were made using the Bonferroni method. Actuarial relapse free survival was calculated using the Kaplan Meier method and using the log rank test. A corrected p-value of less than 0.05 was considered significant and p-values are reported corrected for the number of comparisons, unless indicated otherwise. All data were analyzed retrospectively.
Results
Results Results Results
Patients
In total, between 1990 and July 2005, 418 patients were diagnosed with AAV. In eighty-eight of these patients, HLA typing was not performed, mainly because these patients were seen only once for second opinion (n=76). Of 26 patients, insufficient data were available (10 died shortly after diagnosis, 16 were subsequently treated in other hospitals). In total, 304 patients with AAV with sufficient data and at least 2 years of follow-up could be included. Most of these (79%) were classified as WG and were ANCA positive (94%). Median follow-up was 8 years (range: 2.0-16.8) and ended in July 2007 (Table 1) . HLA antigens in patients with AAV Table 2 shows the distribution of HLA antigens in patients with AAV and in healthy controls. We found a decreased prevalence of DR6 in patients with AAV compared with controls, which was attributable to the split DR13(6) (p<0.0001, OR 0.3 (0.2-0.4)) only, as the split DR14(6) was distributed equally between patients and controls.
There was a tendency towards a lower prevalence of DR1 (p=0.10) in AAV patients. We further found an increased prevalence of DR4 in AAV patients (p<0.0001, OR 1.7 (1.4-2.2)). In addition, the so called ancestral haplotype, consisting of the antigens A1, B8 and DR3, was overrepresented in AAV (19%) compared with Dutch controls originating from a Eurotransplant database (12%, p=0.001, OR 1.8 (1.3-2.4)). Differences in prevalence of A26(10), A11, B5 and the split B51 (5), B17 and the split B57 (17) and DR1 between AAV patients and controls, were no longer significant after correction for multiple comparisons. (14) 968 (18) 24 (9) 42 (14) 1031 (18 # p values significant after correction for multiple comparisons (DR4, DR6 and DR13(6): p<0.0001).
The prevalence of the various HLA antigens did not differ between patients with WG, MPA, RLV and CSS except for DR8, which was more prevalent in patients with CSS (58%) compared with patients with WG, MPA and RLV (p<0.0001) and healthy controls (p<0.0001, OR 21.1 (6.7-66.8)) ( (6) * significantly different compared with controls ** significantly different from both controls and the 3 other diagnoses. Except for DR8, no significant differences between the 4 diagnoses were found.
# compared with 4000 controls from a Eurotransplant database.
All values between brackets are percentages, unless otherwise indicated.
HLA antigens and disease characteristics
We found no associations of HLA antigens with disease activity at diagnosis, as measured by the BVAS score. We found no associations of HLA antigens and clinical characteristics like ENT, lung, renal and peripheral nervous system involvement nor with dialysis-and/or ventilator dependency at diagnosis either (data not shown). Likewise, no differences in organ involvement and dialysis and/or ventilator dependency were found between patients with the ancestral A1B8DR3 haplotype and those without this haplotype (data not shown).
HLA antigens and relapses
Within 5 years after diagnosis, 149 patients (49%) experienced a relapse. We found no significant associations between HLA antigens and the occurrence of relapses or disease free survival. There were also no differences in the occurrence of relapses or disease free survival between patients with or without the ancestral haplotype (data not shown).
HLA antigens and ANCA
Comparing the distribution of HLA antigens between patients with PR3-ANCA and those with MPO-ANCA, we found no differences. Likewise, we found no differences in HLA antigens between the patients who were ANCA negative and those with PR3-or MPO-ANCA at diagnosis. There were also no differences between those who became ANCA negative at least once during the first year of follow-up and those who were persistently ANCA positive. This was true for all AAV patients ANCApositive at diagnosis and for the group with PR3-ANCA and MPO-ANCA separately. As the HLA system plays a central role in the distinction between self and non-self, an association of this system with the autoimmune disease AAV could be present. A clear association would offer an opportunity to further elucidate the etiology of AAV and, if associated with severity or relapse risk, to tailor the treatment to the individual patient. In our study involving 304 patients with AAV, we found DR13(6) being less and DR4 more prevalent compared with healthy controls. In addition, the ancestral haplotype A1B8DR3 was more frequently present in AAV patients than in controls. When analyzed per form of ANCA-associated vasculitis, these associations were found in patients with WG only, although no significant differences in HLA-antigens were found between the four diagnoses. This lack of association between HLAantigens and the subgroups of MPA, RLV and CSS may be due to the small number of patients in these groups, as the antigen distribution was similar between the diagnoses, with the exception of DR8. In addition, compared to controls, DR1 was less prevalent in patients with WG only. Furthermore, in our small cohort of patients with CSS, DR8 was more prevalent than in patients with other forms of vasculitis and controls. No associations were seen between HLA antigens and disease characteristics at presentation or the course of AAV. In addition, there were no differences in HLA antigen distribution between patients with PR3-ANCA and MPO-ANCA. No relation between HLA antigens and the course of AAV was found.
So far, reports with divergent results on the association of HLA antigens with AAV have been published (1-22)(overview in Table 4 ). The divergency of these results and the discrepancy with some of our results may be explained by the small and heterogeneous patient populations with racial and geographical differences that were studied, which is in contrast to our study, which included a large homogeneous cohort of Caucasian AAV patients that was compared with controls from the same region. Our results are in agreement with studies including Caucasian patients (German, British, Dutch). A decreased prevalence of DR13(6), has been reported before in AAV (4;7;10;16). It should be mentioned that part (n=106) of our 304 patients were included in one of these studies as well (10) . These four studies included WG patients mainly, however, in patients with CSS as well, a decrease in DR13(6) was seen (22;29) , being significant in a German study only (29) . In agreement with our findings, an increase of DR4 was reported before (6;10;15;16;22;29). In WG and MPA patients, an increase of DR8 has been described before, but not in patients with CSS, like in our study (8) . The decreased prevalence of DR1 and increased prevalence of the ancestral haplotype in WG patients have not been reported before.
We, like others (3;10;12), found no clear associations between HLA antigens and the disease characteristics at presentation and the course of AAV. In one study, however, a high prevalence of DR4 was seen in a subgroup of PR3-ANCA AAV patients with end stage renal disease (16) . Interestingly, linkage between a TNFα 2a microsatellite and DR4 was found in that study. This may indicate that functional polymorphisms, located in the vicinity of TNF and linked to HLA genes, produce higher levels of TNF, possibly explaining that DR4 is associated with more serious HLA HLA HLA HLA AND AND AND AND ANCA ANCA ANCA ANCA----ASSOCIATED ASSOCIATED ASSOCIATED ASSOCIATED VASCULITIS VASCULITIS VASCULITIS VASCULITIS 29 disease. In agreement with this hypothesis, more constitutional and (a trend to) more vasculitis symptoms were seen in CSS patients carrying DR4 (22) . In contrast, DQ7DR4 was associated with a more favorable course (non-persistence) of ANCA levels in another study (6) . In our study, however, we found no association between HLA-antigens and course of ANCA. The role of HLA antigens in the development of autoimmune diseases, like AAV, is still unclear. Supporting the role for HLA in autoimmunity, is the finding of an increased prevalence of the so-called ancestral haplotype A1B8DR3 in various autoimmune diseases, which is associated with an abnormal functioning (mainly) humoral immune system that predisposes to the development of autoimmune diseases (30) (31) (32) (33) . This haplotype, which is highly prevalent in Northern Europe, is called ancestral because it defines a highly conserved haplotype that is derived from a common remote ancestor. In healthy carriers a shift to a Th2-like response is seen, which enhances the humoral immune response. Furthermore, this haplotype leads to prolonged persistence of (auto-)antigens by increasing apoptosis of lymphocytes and TNF-α production, while complement function is decreased. In addition, linkage with polymorphisms of other immunologically important genes is found (30) (31) (32) (33) . It is therefore very interesting that we found significantly more carriers of the ancestral haplotype A1B8DR3 in patients with WG. Importantly, we did not find a relation between this haplotype and manifestations and relapses of disease and/or ANCA persistence.
The influence of HLA on the development of AAV is probably more complex than described above. For instance, a group of 34 class I and II HLA antigens turned out to influence the percentage of neutrophils expressing PR3 (21) . A high percentage of neutrophils expressing PR3 is a risk factor for (relapses of) AAV (34) . Furthermore, absence of DR13(6) may reduce the ability to prevent infections and thus predisposes to colonisation with Staphylococcus aureus (35) , which is increased in WG and is an established risk factor for relapses of AAV (36) . Moreover, in 150 patients with WG, using an extended association screen, linkage was found between DPB1*0401 and the retinoid X receptor b allele 3, which is involved in several immune functions, like induction of apoptosis (19) . In that study, 202 microsatellites, representing apoptosis-related genes and genes that are downregulated in apoptotic neutrophils, were used to perform this extended association screen. Certain alleles within chromosome 6 were thus identified. Further typing of these alleles identified the retinoid X receptor b allele 3 that was linked to DPB1*0401.
In conclusion, we found an association between AAV and the HLA antigens DR4 and DR13(6) and the ancestral haplotype A1B8DR8, particularly in patients with WG. In addition, we found an association between DR1 and WG, and between DR8 and CSS. How these associations lead to the development of AAV is still unclear. We found no association with HLA antigens and disease characteristics or course of AAV. 
